Cell therapy limits myofibroblast differentiation and structural cardiac remodeling basic fibroblast growth factor-mediated paracrine mechanism

Circulation: Heart Failure

Volumn 5, Issue 3, 2012, Pages 349-356

  Fedak, Paul W M ^a   Bai, Liping ^a   Turnbull, Jeannine ^a   Ngu, Janet ^a   Narine, Kishan ^a   Duff, Henry J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Extracellular matrix; Myofibroblasts; Paracrine; Remodeling

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN GEL; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; PROTEIN INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 2; ACTIN; SMOOTH MUSCLE ACTIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL THERAPY; CELL TRANSPLANTATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DATA ANALYSIS; EXAMINATION; EXTRACELLULAR MATRIX; FISCHER 344 RAT; HEART INFARCTION; HEART MUSCLE CELL; IN VITRO STUDY; MALE; MYOFIBROBLAST; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VASCULAR SMOOTH MUSCLE; ZYMOGRAPHY; ANIMAL; BIOLOGICAL THERAPY; CYTOLOGY; HEART CONTRACTION; HEART VENTRICLE REMODELING; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSPLANTATION;

ACTINS; ANIMALS; CELL DIFFERENTIATION; EXTRACELLULAR MATRIX; FIBROBLAST GROWTH FACTOR 2; MALE; MATRIX METALLOPROTEINASE 2; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOFIBROBLASTS; PARACRINE COMMUNICATION; RATS; RATS, INBRED F344; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE THERAPY; VENTRICULAR REMODELING;

EID: 84864293008     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.111.965889     Document Type: Article

References (33)

1. Karla K, Dinesh K, Biykem B, Feng W, Ziad D, Yukihiro S, George B, David E, Natarajan S, Douglas LM. Cardiac remodeling as a consequence and cause of progressive heart failure. Clinical Cardiology. 1998;21:14-19.
2. Fedak PW, Weisel RD, Verma S, Mickle DA, Li RK. Restoration and regeneration of failing myocardium with cell transplantation and tissue engineering. Semin Thorac Cardiovasc Surg. 2003;15:277-286.
3. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007;87: 1285-1342.
4. Peterson JT, Li H, Dillon L, Bryant JW. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res. 2000;46:307-315.
5. Vanhoutte D, Schellings M, Pinto Y, Heymans S. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res. 2006;69:604-613.
6. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodeling. Lancet. 2006;367:356-367.
7. Bergman MR, Teerlink JR, Mahimkar R, Li L, Zhu BQ, Nguyen A, Dahi S, Karliner JS, Lovett DH. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol. 2007;292:H1847-H1860.
8. Kandalam V, Basu R, Abraham T, Wang X, Soloway PD, Jaworski DM, Oudit GY, Kassiri Z. TIMP2 deficiency accelerates adverse postmyocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ Res. 2010;106:796-808.
9. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol. 2005;45:657-687.
10. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63:423-432.
11. Sun Y, Weber KT. Infarct scar: a dynamic tissue. Cardiovasc Res. 2000;46:250-256.
12. Fedak PW. Paracrine effects of cell transplantation: modifying ventricular remodeling in the failing heart. Semin Thorac Cardiovasc Surg. 2008;20: 87-93.
13. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008;103:1204-1219.
14. Allaire E, Muscatelli-Groux B, Mandet C, Guinault AM, Bruneval P, Desgranges P, Clowes A, Melliere D, Becquemin JP. Paracrine effect of vascular smooth muscle cells in the prevention of aortic aneurysm formation. J Vasc Surg. 2002;36:1018-1026.
15. Li RK, Jia ZQ, Weisel RD, Merante F, Mickle DA. Smooth muscle cell transplantation into myocardial scar tissue improves heart function. J Mol Cell Cardiol. 1999;31:513-522.
16. Fedak PW, Szmitko PE, Weisel RD, Altamentova SM, Nili N, Ohno N, Verma S, Fazel S, Strauss BH, Li RK. Cell transplantation preserves matrix homeostasis: a novel paracrine mechanism. J Thorac Cardiovasc Surg. 2005;130:1430-1439.
17. Yoo KJ, Li RK, Weisel RD, Mickle DA, Li G, Yau TM. Autologous smooth muscle cell transplantation improved heart function in dilated cardiomyopathy. Ann Thorac Surg. 2000;70:859-865.
18. Tian H, Cimini M, Fedak PW, Altamentova S, Fazel S, Huang ML, Weisel RD, Li RK. TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction. J Mol Cell Cardiol. 2007;43:733-743.
19. Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol. 2005;289:H501-H512.
20. Narine K, De Wever O, Van Valckenborgh D, Francois K, Bracke M, DeSmet S, Mareel M, Van Nooten G. Growth factor modulation of fibroblast proliferation, differentiation, and invasion: implications for tissue valve engineering. Tissue Eng. 2006;12:2707-2716.
21. Khouw IM, van Wachem PB, Plantinga JA, Vujaskovic Z, Wissink MJ, de Leij LF, van Luyn MJ. TGF-beta and bFGF affect the differentiation of proliferating porcine fibroblasts into myofibroblasts in vitro. Biomaterials. 1999;20:1815-1822.
22. Lijnen P, Petrov V, Rumilla K, Fagard R. Transforming growth factor-beta 1 promotes contraction of collagen gel by cardiac fibroblasts through their differentiation into myofibroblasts. Methods Find Exp Clin Pharmacol. 2003;25:79-86.
23. Yasuda T, Weisel RD, Kiani C, Mickle DA, Maganti M, Li RK. Quantitative analysis of survival of transplanted smooth muscle cells with real-time polymerase chain reaction. J Thorac Cardiovasc Surg. 2005;129:904-911.
24. Bryant JE, Shamhart PE, Luther DJ, Olson ER, Koshy JC, Costic DJ, Mohile MV, Dockry M, Doane KJ, Meszaros JG. Cardiac myofibroblast differentiation is attenuated by alpha(3) integrin blockade: potential role in post-MI remodeling. J Mol Cell Cardiol. 2009;46:186-192.
25. Suzuki T, Akasaka Y, Namiki A, Ito K, Ishikawa Y, Yamazaki J, Ishii T. Basic fibroblast growth factor inhibits ventricular remodeling in Dahl salt-sensitive hypertensive rats. J Hypertens. 2008;26:2436-2444.
26. Virag JA, Rolle ML, Reece J, Hardouin S, Feigl EO, Murry CE. Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function. Am J Pathol. 2007;171:1431-1440.
27. Brown RD, Jones GM, Laird RE, Hudson P, Long CS. Cytokines regulate matrix metalloproteinases and migration in cardiac fibroblasts. Biochem Biophys Res Commun. 2007;362:200-205.
28. Angoulvant D, Fazel S, Weisel RD, Lai TY, Fedak PW, Chen L, Rafati S, Seneviratne CK, Degousee N, Li RK. Cell-based gene therapy modifies matrix remodeling after a myocardial infarction in tissue inhibitor of matrix metalloproteinase-3-deficient mice. J Thorac Cardiovasc Surg. 2009;137:471-480.
29. Singla DK, McDonald DE. Factors released from embryonic stem cells inhibit apoptosis of H9c2 cells. Am J Physiol Heart Circ Physiol. 2007; 293:H1590-H1595.
30. Morley ME, Riches K, Peers C, Porter KE. Hypoxic inhibition of human cardiac fibroblast invasion and MMP-2 activation may impair adaptive myocardial remodeling. Biochem Soc Trans. 2007;35:905-907.
31. Fedak PW, Smookler DS, Kassiri Z, Ohno N, Leco KJ, Verma S, Mickle DA, Watson KL, Hojilla CV, Cruz W, Weisel RD, Li RK, Khokha R. TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation. 2004;110: 2401-2409.
32. Lovelock JD, Baker AH, Gao F, Dong JF, Bergeron AL, McPheat W, Sivasubramanian N, Mann DL. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol. 2005;288:H461-H468.
33. Fedak PW, Altamentova SM, Weisel RD, Nili N, Ohno N, Verma S, Lee TY, Kiani C, Mickle DA, Strauss BH, Li RK. Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. Am J Physiol Heart Circ Physiol. 2003;284:H626-H634.